Mother Suffering with NCPH and Hypersplenism Successfully Delivers Baby At BirthRight by Rainbow Hospitals Hyderabad 3rd May 2024: BirthRight by Rainbow Hospitals Financial District and Star Hospitals in a collaborative effort have showcased ...
KYOTO, Japan , April 26, 2024 /PRNewswire/ -- OMRON Healthcare Co., Ltd. based in Muko, Kyoto Prefecture , Japan , announces to be the official sponsor of May Measurement Month (MMM,) a global campaign to raise awareness of blood ...
World pulmonary hypertension community to unite on May 5 to raise awareness, offer support and advocate for PH. WASHINGTON , April 24, 2024 /PRNewswire-PRWeb/ -- The Pulmonary Hypertension Association will unite with over 80 ...
Team PHenomenal Hope (Team PH) seeks submissions for its PHenomenal Impact Fund for Global PH Research, marking the sixth consecutive year of funding innovative studies in pulmonary hypertension (PH) WHEATON, IL , Feb. 15, 2024 ...
INCHEON, South Korea , Feb. 7, 2024 /PRNewswire/ -- Zymedi announced today that the first in human dosage of ZMA001, a monoclonal antibody being developed as a first-in-class treatment for Pulmonary Arterial Hypertension (PAH) has been ...
SoniVie announces enrollment completion in the REDUCED-1 pilot study TEL AVIV, Israel , Jan. 31, 2024 /PRNewswire/ -- SoniVie , an Israeli company developing a novel, proprietary Therapeutic Intra-Vascular Ultrasound (TIVUS TM ) System ...
Team PHenomenal Hope, a nonprofit advocacy organization, has published a research paper in Pulmonary Circulation titled "Patient perspectives on pulmonary hypertension in the United States : Burdens, expectations, and goals." The study ...
TAIPEI , Oct. 30, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announced today that the company will be presenting at the American Heart Association (AHA) 2023 Annual Meeting taking place in Philadelphia, PA , ...
SEOUL, South Korea , July 2, 2023 /PRNewswire/ -- Today Zymedi, a Korean biotech venture-backed company, announced the signing of a clinical Cooperative Research and Development Agreement (CRADA) with the National Heart, Lung, and Blood ...
This is the first and only single tablet combination therapy application to be submitted for review in the U.S. for this rare, progressive disease If approved, Janssen's comprehensive PAH portfolio has the potential to cover all ...
More than 30% of adults globally suffer from hypertension, a major controllable risk factor for cardiovascular disease and mortality. Hypertension is characterized by either high systolic blood pressure (SBP) and, or high diastolic blood pressure ...
Systolic blood pressure , representing arterial pressure during heartbeats, emerged as a pivotal predictor of stroke risk among Type 2 diabetes mellitus patients ...
Getting less than seven hours of sleep is linked to an increased likelihood of developing high blood pressure in the long run. Sleeping less than seven hours was linked to a 7%...
Combining two or more blood pressure medications can markedly lower blood pressure in patients on ibrutinib. ( ) Targeted drugs such as ibrutinib have improved outcomes for patients with cancers of the lymphatic system, but patients treated ...
Group of international experts advocates for a crucial change in hypertension treatment guidelines, urging the inclusion of recommendations for low-sodium potassium-enriched salt to enhance high blood pressure control as published in the American ...
Subscribe to our Free Newsletters!
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.
Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2024
Careers